Merck & Co., Inc. Wins First Stage of the PD-1 Race

Merck gains FDA approval for Keytruda, but the race isn't over yet.

Sep 4, 2014 at 10:55PM

Source: Merck.

Merck (NYSE:MRK) has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or unresectable melanoma who are no longer responding to other drugs.

It's good news for sure, but the development of PD-1 drugs is like the Tour de France with multiple stages. Merck might be wearing the yellow jersey right now, but it's far from winning it all. Shares of the company hardly budged on the news, highlighting the relative insignificance of this approval (and the fact that it was widely expected).

Multiple indications
The PD-1 pathway allows the immune system to recognize cells as human and tells the immune system not to attack them.

Many tumor cells have enough mutations in them that the immune system would recognize them as foreign, but they still have the PD-1 pathway that shuts down the attack. PD-1 drugs block the pathway, allowing the immune system to do its job.

PD-1 isn't tumor-specific, so Merck is testing Keytruda in a wide variety of cancers. Beyond melanoma, there are clinical trials in everything from lung cancer to kidney cancer and even some blood cancers like multiple myeloma. In many cases, it can be used in combination with current targeted cancer drugs. For example, Merck is working with GlaxoSmithKline (NYSE:GSK) to test the combination of Keytruda with GlaxoSmithKline's Votrient in kidney cancer. 

In the grand scheme of things, advancing into those other cancers and getting approved as a first-line therapy for melanoma is more important than the current approval for melanoma patients using it as a last resort.

Of course, being on the market (for any indication) would allow the drug to be used by doctors off-label to treat other types of cancer, which is probably the main reason Merck pushed to get Keytruda approved.

The competition
Merck isn't the only company going after the PD-1 pathway. Bristol-Myers Squibb's (NYSE:BMY) Opdivo is already on the market in Japan. The company plans to submit an application to market Opdivo in the U.S. this quarter, theoretically putting it eight to nine months behind Keytruda, but Merck got its approval almost two months early, so the delay could be shorter.

For lung cancer, Bristol-Myers might actually be first to approval. The company is working on a rolling submission with the FDA, with plans to complete the submission by the end of the year. 

Roche and AstraZeneca (NYSE:AZN) also have drugs that target the PD-1 pathway, but they're further behind and not an immediate threat (at the moment).

A long race
We can't declare a winner because we're still waiting on the phase 3 data for lung cancer and later for other indications. How long the drugs are able to extend survival will ultimately determine the winner. Of course, there are so many opportunities here, there are likely to be niches for each of the drugs to fit into.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers